Detailed Analysis of Stereotactic Radiation Therapy Market by Linear Accelerator Radiosurgery Systems, GammaKnife Radiosurgery Systems, Proton Beam Therapy, and CyberKnife 2023 to 2033

<p>The global <strong>stereotactic radiation therapy market</strong> was valued at US$ 3.7 Billion in 2022 and is expected to reach US$ 7.9 Billion by 2033. The linear accelerator radiosurgery systems with around 68.9% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 5.2% over the forecast period (2023 to 2033)</p><table><tbody><tr><th scope='row'>Data Points</th><td>Market Insights</td></tr><tr><th scope='row'>Market Value 2022</th><td>US$ 3.7 Billion</td></tr><tr><th scope='row'>Market Value 2023</th><td>US$ 3.9 Billion</td></tr><tr><th scope='row'>Market Value 2033</th><td>US$ 7.9 Billion</td></tr><tr><th scope='row'>CAGR 2023 to 2033</th><td>7.3%</td></tr><tr><th scope='row'>Market Share of Top 5 Countries</th><td>62.6%</td></tr><tr><th scope='row'>Key Market Players</th><td>Mevion Medical Systems, Inc., Accuray Incorporated, MASEP Medical Science &amp; Technology Development (Shenzhen) Co, Akesis, Inc., Elekta, Hitachi, Ltd. (Mitsubishi Electric Corporation), Siemens Healthineers AG (Varian Medical Systems, Inc.), Ion Beam Applications, ProTom International, Pronova Solutions, Sumitomo Heavy Industries, Ltd., Provision Cares, Optivus Proton Therapy Inc., Advanced Oncotherapy, Sun Nuclear Corporation, and B dot Medical Inc. (partnered with Toshiba)</td></tr></tbody></table><p>Report Scope as Per Stereotactic Radiation Therapy Industry Analysis</p><table><tbody><tr><th scope='row'>Attribute</th><td>Details</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Historical Data Available for</th><td>2017 to 2022</td></tr><tr><th scope='row'>Market Analysis</th><td>US$ Million for Value, Units for Volume</td></tr><tr><th scope='row'>Key Regions Covered</th><td>North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA)</td></tr><tr><th scope='row'>Key Countries Covered</th><td>USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Australia, New Zealand, GCC countries, T&uuml;rkiye, Israel, Northern Africa and South Africa.</td></tr><tr><th scope='row'>Key Market Segments Covered</th><td>Technology, Indication, End User, and Region</td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Mevion Medical Systems, Inc.</li><li>Hitachi, Ltd. (Mitsubishi Electric Corporation)</li><li>Accuray Incorporated</li><li>MASEP Medical Science &amp; Technology Development (Shenzhen) Co</li><li>Akesis, Inc</li><li>Elekta</li><li>Siemens Healthineers AG (Varian Medical Systems, Inc.)</li><li>Ion Beam Applications</li><li>ProTom International</li><li>Pronova Solutions</li><li>Sumitomo Heavy Industries, Ltd.</li><li>Provision Cares</li><li>Optivus Proton Therapy Inc.</li><li>Advanced Oncotherapy</li><li>Sun Nuclear Corporation</li><li>B dot Medical Inc. (partnered with Toshiba)</li></ul></td></tr><tr><th scope='row'>Report Coverage</th><td>Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives</td></tr><tr><th scope='row'>Pricing</th><td>Available upon Request</td></tr></tbody></table>

<p>全球立体定向放射治疗市场在2022年达到了37亿美元的价值，预计到2033年将达到79亿美元。在2022年，拥有约68.9%价值份额的直线加速器立体定向放射治疗系统在全球产品类别中位居首位，并预计在预测期内（2023年至2033年）以接近5.2%的复合年增长率增长。</p><table><tbody><tr><th scope='row'>数据点</th><td>市场洞察</td></tr><tr><th scope='row'>2022年市场价值</th><td>37亿美元</td></tr><tr><th scope='row'>2023年市场价值</th><td>39亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>79亿美元</td></tr><tr><th scope='row'>2023至2033年复合年增长率</th><td>7.3%</td></tr><tr><th scope='row'>前五名国家市场份额</th><td>62.6%</td></tr><tr><th scope='row'>主要市场参与者</th><td>梅沃安医疗系统公司（Mevion Medical Systems, Inc.）、阿库雷公司（Accuray Incorporated）、玛斯普医学科学与技术发展（深圳）有限公司（MASEP Medical Science & Technology Development (Shenzhen) Co）、阿凯西斯公司（Akesis, Inc.）、伊莱克特拉公司（Elekta）、日立有限公司（Hitachi, Ltd.）（三菱电机股份有限公司）、西门子医疗保健公司（Siemens Healthineers AG）（瓦里安医疗系统公司，Varian Medical Systems, Inc.）、离子束应用公司（Ion Beam Applications）、普罗托姆国际公司（ProTom International）、普罗诺瓦解决方案公司（Pronova Solutions）、住友重工业有限公司（Sumitomo Heavy Industries, Ltd.）、普罗维森护理公司（Provision Cares）、奥蒂维斯质子治疗公司（Optivus Proton Therapy Inc.）、先进肿瘤治疗公司（Advanced Oncotherapy）、太阳核公司（Sun Nuclear Corporation）和贝德医疗公司（B dot Medical Inc.）（与东芝合作）</td></tr></tbody></table><p>根据立体定向放射治疗行业分析报告范围</p><table><tbody><tr><th scope='row'>属性</th><td>详细信息</td></tr><tr><th scope='row'>预测期</th><td>2023年至2033年</td></tr><tr><th scope='row'>可提供的历史数据</th><td>2017年至2022年</td></tr><tr><th scope='row'>市场分析</th><td>以百万美元为单位的价值，以单位为体积</td></tr><tr><th scope='row'>主要覆盖地区</th><td>北美、拉丁美洲、欧洲、南亚、东亚、大洋洲、中东和非洲（MEA）</td></tr><tr><th scope='row'>主要覆盖国家</th><td>美国、加拿大、巴西、墨西哥、阿根廷、德国、意大利、法国、英国、西班牙、比荷卢、俄罗斯、斯堪的纳维亚、中国、日本、韩国、印度、印度尼西亚、泰国、菲律宾、越南、马来西亚、澳大利亚、新西兰、海湾合作委员会国家、土耳其、以色列、北非和南非。</td></tr><tr><th scope='row'>主要市场细分</th><td>技术、指征、终端用户和地区</td></tr><tr><th scope='row'>主要公司简介</th><td><ul><li>梅沃安医疗系统公司（Mevion Medical Systems, Inc.）</li><li>日立有限公司（Hitachi, Ltd.）（三菱电机股份有限公司）</li><li>阿库雷公司（Accuray Incorporated）</li><li>玛斯普医学科学与技术发展（深圳）有限公司（MASEP Medical Science & Technology Development (Shenzhen) Co）</li><li>阿凯西斯公司（Akesis, Inc）</li><li>伊莱克特拉公司（Elekta）</li><li>西门子医疗保健公司（Siemens Healthineers AG）（瓦里安医疗系统公司，Varian Medical Systems, Inc.）</li><li>离子束应用公司（Ion Beam Applications）</li><li>普罗托姆国际公司（ProTom International）</li><li>普罗诺瓦解决方案公司（Pronova Solutions）</li><li>住友重工业有限公司（Sumitomo Heavy Industries, Ltd.）</li><li>普罗维森护理公司（Provision Cares）</li><li>奥蒂维斯质子治疗公司（Optivus Proton Therapy Inc.）</li><li>先进肿瘤治疗公司（Advanced Oncotherapy）</li><li>太阳核公司（Sun Nuclear Corporation）</li><li>贝德医疗公司（B dot Medical Inc.）（与东芝合作）</li></ul></td></tr><tr><th scope='row'>报告覆盖范围</th><td>市场预测、竞争情报、DROT分析、市场动态和挑战、战略增长举措</td></tr><tr><th scope='row'>定价</th><td>根据要求提供</td></tr></tbody></table>